phosphodiesterases


Also found in: Dictionary, Acronyms, Encyclopedia.

phos·pho·di·es·ter·as·es

(fos'fō-dī-es'tĕr-ās'ĕz),
Enzymes cleaving bonds in phosphodiesters, such as those in cAMP or between nucleotides in nucleic acids, liberating smaller polynucleotide or oligonucleotide units or mononucleotides but not orthophosphate.

phos·pho·di·es·ter·as·es

(fos'fō-dī-es'tĕr-ās-ĕz)
Enzymes cleaving phosphodiester bonds, such as those in cyclic adenosine monophosphate or between nucleotides in nucleic acids, liberating smaller poly- or oligonucleotide units or mononucleotides but not inorganic phosphate.
References in periodicals archive ?
The database also includes pharmaceutical companies, biotech companies, CROs, hospitals, government labs and other organisations active in the Phosphodiesterases research field.
Verona's lead drug, RPL554, is a dual phosphodiesterase (PDE) 3
Plexxikon has advanced to lead discovery in three protein families, including protein kinases, phosphodiesterases and nuclear receptors, targeting oncology, sexual dysfunction, inflammation and metabolic disorders.
It achieves this selectivity by inhibiting certain cyclic GMP phosphodiesterases that are expressed at high levels in the abnormal cells, thus freeing those damaged cells to die through normal cellular processes.
Broad spectrum inhibition of cGMP phosphodiesterases has been shown to lead to elevation in cGMP levels and the sustained activation of Protein-Kinase G (PKG).
Research has previously shown that these drugs act by inhibiting certain cellular proteins called cyclic GMP phosphodiesterases (cGMP PDEs) that are overexpressed in a variety of tumor types.
It achieves this selective activity by inhibiting certain cyclic GMP phosphodiesterases that are expressed at high levels in the abnormal cells, thus freeing those damaged cells to die through normal cellular processes.
In addition to NRs and GPCRs, additional modules of the DrugTarget Database include ion channels, protein kinases, protein phosphatases, phosphodiesterases, transporters, and proteases.
CP461 and Cell Pathways' other selective apoptotic antineoplastic drugs (SAANDs) inhibit cyclic GMP (cGMP) phosphodiesterases 2 and 5, resulting in the activation of protein kinase G and the triggering of downstream cellular pathways leading to apoptosis (programmed cell death).

Full browser ?